His career has included pharmacy practice in a variety of settings, as well as teaching, research, publications, and consultations in pharmacology, pharmacy, and nutrition to industry, government, health care, publishing and legal fields.
He is Associate Professor of Pharmacology at the Rush University Medical Center in Chicago, where he served as the Course Director for the Medical Pharmacology program. He also held Faculty appointments at the University of Illinois Colleges of Medicine and Pharmacy.
Dr. O’Donnell is a Diplomate of the American Board of Clinical Pharmacology, a fellow of the American College of Clinical Pharmacology, a fellow of the American College of Nutrition, Founding Editor-in-Chief of the Journal of Pharmacy Practice, and Editor of Drug Injury: Liability, Analysis, and Prevention, First Edition (2001), Second Edition (2005), Third Edition (2012), and Co-editor of O’Donnell’s Drug Injury Fourth Edition (2016); a Co-Editor Pharmacy Law: Litigating Pharmaceutical Cases (1995), and The Process of New Drug Discovery and Development, Second Edition (CRC Press 2005), and co-editor of Drug Discovery and Development Third Edition (2019).
He consults and testifies in matters involving pharmaceuticals, medication errors, nutritionals, dietary supplements, alcohol and recreational drug toxicity, and drug injuries throughout the United States, for defense and plaintiffs’ counsel. Dr. O’Donnell received a Bachelor of Science in Pharmacy from the University of Illinois, a Doctor of Pharmacy from the University of Michigan, and a Master of Science in Clinical Nutrition from Rush University.
He is an Associate Professor at Rosalind Franklin University of Medicine and Science, where he teaches pharmacology in the Chicago Medical School and the College of Pharmacy.
He is also a guest lecturer in Pharmacology at Rush University Medical Center. He served as an NIH T32 Training Grant Postdoctoral Fellow in Respiratory Biology at the University of Chicago. He also held a postdoctoral appointment at the Indiana University School of Medicine at South Bend.
His medical research principally focused on inflammatory diseases. Additionally, he conducted organometallic chemistry research at the University of Wisconsin-Madison and at Northwestern University in Evanston, IL.
Dr. O’Donnell is a member of the American Society for Pharmacology and Experimental Therapeutics, American College of Clinical Pharmacology, and the American Academy of Clinical Toxicology.
He has particular interests in the microbiome research, computational research in pharmacology, pharmacokinetics, and analytical toxicology.
He received his Bachelor’s Degree in Electrical Engineering and Computer Sciences from the Massachusetts Institute of Technology (MIT), a Masters Degree in Chemistry from the University of Wisconsin-Madison, and a Doctor of Philosophy in Pharmacology from Rush University Medical Center in Chicago.
He is a Co-Editor of O’Donnells Drug Injury, Fourth Edition and the Chief Editor of Drug Discovery and Development – Third Edition. Dr. O’Donnell consults in drug injury, analytical toxicology, and other related matters.
Presents up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace.
It explores many scientific advances in new drug discovery and development for areas such as screening technologies, biotechnology approaches, and evaluation of efficacy and safety of drug candidates through preclinical testing.
This book also greatly expands the focus on the clinical pharmacology, regulatory, and business aspects of bringing new drugs to the market and offers coverage of essential topics for companies involved in drug development. Historical perspectives and predicted trends are also provided.
Editor:
James T. O’Donnell, James J. O’Donnell and 48 Contributors
ISBN 10:
1-936360-44-6
Copyright Date Ed:
2016
Pages:
983; 50 chapters
Binding Information:
Casebound Size: 8.5″ X 11″ Inches
Availability:
In stock.
Price (shipping included):
$315.00
Presents up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace.
It explores many scientific advances in new drug discovery and development for areas such as screening technologies, biotechnology approaches, and evaluation of efficacy and safety of drug candidates through preclinical testing.
This book also greatly expands the focus on the clinical pharmacology, regulatory, and business aspects of bringing new drugs to the market and offers coverage of essential topics for companies involved in drug development. Historical perspectives and predicted trends are also provided.
Editors:
ISBN 10:
978-1-13-808026-3
Copyright Date Ed:
2019
Pages:
668; 28 chapters
Availability:
In stock.
Price (shipping included):
$250.00
Compliance, or now more recently called adherence, is a topic well known to clinicians. Lack of taking medications results in the loss of any beneficial effects of any type of chronic (or even acute) drug therapy.
The topic was addressed in a recent murder trial in Cook County (Chicago, IL). For those of you who are health care professionals, this may interest you. For the lawyers, and do criminal (and possibly) civil law, the topic of compliance and adherence may be addressed in a variety of cases, not just murder cases.
Pharmaconsultant Partner, James J. O’Donnell PhD recently presented a seminar to the Lake County (IL) Dental (Society) on the topic of Marijuana: Considerations in Dental Practice. The PPT presentation provides a thorough review of marijuana pharmacology and toxicology information in general, and specific information relevant to Dentists. Anyone litigating (or using) marijuana may find this information useful and interesting. (PDF, 55 Slides)
Marijuana usage is ubiquitous and growing, but not without consequences. Whatever your practice, marijuana may be involved. View the presentation delivered at PACDL DUI & Motor
We have been consulted in numerous interesting cases that demonstrate that even drugs deemed generally safe for use can show serious side effects if certain factors go wrong.
If the drug dosing is incorrect, if the drug is not administered properly, if too much drug is given (overdose),
The Opioid Epidemic dominated the news for several years; Covid 19 virus pandemic has quieted the news but not the epidemic. We published a short article on the history and lessons learned for your information. Pharmaconsultant experts have consulted and testified extensively in opiate toxicity cases.
Cannabis (marijuana) is classified as a schedule-I controlled substance, currently not accepted for medical use and with a high potential for abuse. As stated in a previous P&T article, although marijuana remains illegal at the federal level, 33 states have legalized its medical use for certain indications and 10 have legalized its recreational use.
Among those states are differing laws that regulate the possession or supply of usable marijuana, with certain states providing more flexibility than others when it comes to using medical marijuana.